The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
MJFF Research Grant, 2010Role of mGluR4 in the Modulation of Levodopa-induced Motor Performance and Dyskinesia
Objective/Rationale:
Dyskinesias are uncontrollable involuntary body movements that constitute a major clinical problem associated with the long term treatment of Parkinson’s disease (PD) using... -
MJFF Research Grant, 2010Developing Circuit-Targeting Optogenetic Strategies for Pre-Clinical Model Motor Circuitry
Objective/Rationale:
Optogenetics is a new technology that allows control of brain cells with light- in a way that allows targeting of control to well-defined subsets of cells in vivo, even if those... -
MJFF Research Grant, 2010Regulation of LRRK2 Membrane Association
Objective/Rationale:
Mutations in LRRK2 are the most common genetic cause of Parkinson’s disease. The LRRK2 gene encodes a large multi-domain protein with kinase activity. LRRK2 protein is normally... -
MJFF Research Grant, 2010Multi-tracer positron emission tomography (PET) functional imaging as a tool to assess the relevance of rodent LRRK2 models to the human neurochemical phenotype associated with LRRK2 mutations related Parkinsonism
Objective/Rationale:
Transgenic pre-clinical models are instrumental to investigate mutation-induced abnormalities at the bio-chemical, cellular level in a manner not possible in humans. In humans... -
Therapeutics Development Initiative, 2010HE3286 as Treatment for Parkinson's Disease
Objective/Rationale:
Dehydroepiandrosterone (DHEA), a common neutraceutical and potent neuro-steroid has been suggested as a neuroprotective treatment for Parkinson’s disease (PD). However, DHEA is... -
Therapeutics Development Initiative, 2010A Novel Prodrug of Acamprosate for Treatment of L-DOPA-Induced Dyskinesias
Objective/Rationale:
The primary objective of this proposal is to determine if a prodrug of acamprosate could inhibit L-DOPA induced dyskinesias (LID). Functional interactions between the dopamine...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.